(Q36169091)

12 August 2017

Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia (English)

1 reference

12 August 2017

1 reference

1 reference

Annie Viala

1

1 reference

12 August 2017

Françoise Cornic

series ordinal

2

1 reference

12 August 2017

Marie-Noëlle Vacheron

series ordinal

3

1 reference

12 August 2017

language of work or name

1 reference

3 April 2012

1 reference

Schizophrenia Research and Treatment

12 August 2017

1 reference

12 August 2017

2012

1 reference

12 August 2017

368687

1 reference

Creative Commons Attribution 3.0 Unported

12 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Suicide risk in first episode psychosis: a selective review of the current literature

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

The cost of relapse and the predictors of relapse in the treatment of schizophrenia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Clinical guideline recommendations for antipsychotic long-acting injections

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Is early intervention in psychosis cost-effective over the long term?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

The case for long-acting antipsychotic agents in the post-CATIE era.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Review of treatments that can ameliorate nonadherence in patients with schizophrenia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Relapse in schizophrenia: costs, clinical outcomes and quality of life

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Partial compliance and patient consequences in schizophrenia: our patients can do better.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Interventions to improve medication adherence in schizophrenia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Systematic review of patient and nurse attitudes to depot antipsychotic medication.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Medication adherence of individuals with a first episode of psychosis

2 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

The global costs of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

Outcomes for 236 patients from a 2-year early intervention in psychosis service.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

Association between symptomatic remission and functional outcome in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

10-year trends in the treatment and outcomes of patients with first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F368687

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420640

Health resource utilization associated with switching to risperidone long-acting injection

23 September 2018

1 reference

12 December 2020

Does Treatment Adherence Therapy reduce expense of healthcare use in patients with psychotic disorders? Cost-minimization analysis in a randomized controlled trial

1 reference

12 December 2020

Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication

1 reference

12 December 2020

Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia

1 reference

12 December 2020

[Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec]

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/368687

1 reference

release_xxr3x7kafncibgvizhz4u3ynha

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xxr3x7kafncibgvizhz4u3ynha

24 November 2022

mapped directly with Wikidata item

1 reference

12 August 2017

PubMed publication ID

22966435

1 reference